TY - JOUR
T1 - Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva
AU - Cracchiolo, Bernadette M.
AU - Heller, Debra S.
AU - Clement, Paul M.J.
AU - Wolff, Edith C.
AU - Park, Myung Hee
AU - Hanauske-Abel, Hartmut M.
N1 - Funding Information:
The authors gratefully acknowledge the technical expertise of Dana Settembre, and thank Prof. Dr. Axel-Rainer Hanauske, Chair of the Department of Medicine, St. George University Hospital, Hamburg, Germany, for elucidating discussions on the clinical implications of immunoreagents and chemicals directed against mature eIF5A. B.M.C. was in part supported by the UMDNJ Foundation (19–99). H.M.H.-A. is a Scholar in the BIRCWH Program of the NIH (HD-1457). The diagnostic and therapeutic potential of NIH-353 and like reagents is subject of a patent application by UMDNJ and NIH.
PY - 2004/7
Y1 - 2004/7
N2 - Objective. The mature eukaryotic translation initiation factor 5A contains the unusual amino acid hypusine, formed post-translationally from a specific lysine residue and essential for proliferation of eukaryotic cells. We hypothesized that the major eIF5A isoform, eIF5A-1, is an in situ biomarker for proliferation. NIH-353, a polyclonal immunoreagent specific for hypusine-containing eIF5A-1, was used to test this proposal in biopsies of vulvar high-grade intraepithelial neoplasia (VIN), characterized by the presence of proliferating cells throughout the thickness of the epithelium. Methods. Formalin-fixed and paraffin-embedded archival samples with an independently established diagnosis of VIN 3 were stained immunohistochemically after antigen retrieval, employing NIH-353 and, for comparison, the standard Ki-67 antibody. Results. NIH-353 labeled neoplastic keratinocytes throughout the thickness of the epithelium in all VIN 3 samples. Malignant cells in a case of focally invasive squamous cell carcinoma also stained strongly for mature, hypusine-containing eIF5A-1. Epithelium adjacent to these lesions, though still of apparently normal morphology, was immunoreactive throughout its full thickness. At inflammatory foci of lesional sites, solitary reactive lymphocytes were positive, as were individual proliferating cells within dermal appendages. The submucosal stroma lacked reactive cells. Conclusion. NIH-353 identifies mature eIF5A-1 as an in situ biomarker for proliferation. Like Ki-67, this immunoreagent promises broad applicability in histopathological diagnosis and may be helpful in outcome prediction. In contrast to Ki-67, NIH-353 visualizes a molecular target for antineoplastic therapy, and thus may guide the development and clinical testing of drugs that, like the fungicide ciclopirox, inhibit hypusine formation and cell proliferation.
AB - Objective. The mature eukaryotic translation initiation factor 5A contains the unusual amino acid hypusine, formed post-translationally from a specific lysine residue and essential for proliferation of eukaryotic cells. We hypothesized that the major eIF5A isoform, eIF5A-1, is an in situ biomarker for proliferation. NIH-353, a polyclonal immunoreagent specific for hypusine-containing eIF5A-1, was used to test this proposal in biopsies of vulvar high-grade intraepithelial neoplasia (VIN), characterized by the presence of proliferating cells throughout the thickness of the epithelium. Methods. Formalin-fixed and paraffin-embedded archival samples with an independently established diagnosis of VIN 3 were stained immunohistochemically after antigen retrieval, employing NIH-353 and, for comparison, the standard Ki-67 antibody. Results. NIH-353 labeled neoplastic keratinocytes throughout the thickness of the epithelium in all VIN 3 samples. Malignant cells in a case of focally invasive squamous cell carcinoma also stained strongly for mature, hypusine-containing eIF5A-1. Epithelium adjacent to these lesions, though still of apparently normal morphology, was immunoreactive throughout its full thickness. At inflammatory foci of lesional sites, solitary reactive lymphocytes were positive, as were individual proliferating cells within dermal appendages. The submucosal stroma lacked reactive cells. Conclusion. NIH-353 identifies mature eIF5A-1 as an in situ biomarker for proliferation. Like Ki-67, this immunoreagent promises broad applicability in histopathological diagnosis and may be helpful in outcome prediction. In contrast to Ki-67, NIH-353 visualizes a molecular target for antineoplastic therapy, and thus may guide the development and clinical testing of drugs that, like the fungicide ciclopirox, inhibit hypusine formation and cell proliferation.
KW - EIF5A-1
KW - Intraepithelial neoplasia
KW - Vulva
UR - http://www.scopus.com/inward/record.url?scp=3242721547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242721547&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2004.03.018
DO - 10.1016/j.ygyno.2004.03.018
M3 - Article
C2 - 15262146
AN - SCOPUS:3242721547
SN - 0090-8258
VL - 94
SP - 217
EP - 222
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -